Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Erik H. van Beers"'
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Autor:
Joske Ubels, Pieter Sonneveld, Erik H. van Beers, Annemiek Broijl, Martin H. van Vliet, Jeroen de Ridder
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-10 (2018)
Selection of the right cancer treatment is still a challenge. Here, the authors introduce a framework to analyze treatment benefits, using the idea that patients with similar genetic tumor profiles receiving different treatments can be used to model
Externí odkaz:
https://doaj.org/article/bc84203d4d9b4efaa0dbb9de2ebf654a
Autor:
Pieter Sonneveld, Mark van Duin, Daphne Huigh, Rowan Kuiper, Martin H. van Vliet, Lizanne Bosman, Belinda Dumee, Leonie de Best, Marieke Spaan, Erik H. van Beers
Publikováno v:
Journal of Molecular Diagnostics, 23(1), 120-129. Elsevier Inc.
The Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics
Multiple myeloma (MM) is an incurable plasma cell cancer with a large variability in survival. Patients with MM classified as high risk by the SKY92 gene expression classifier are at high risk of relapse and short survival. Analytical validation of t
Autor:
Rowan Kuiper, Yan-Ting Chen, Stefania Oliva, Erik T. Valent, Torsten Haferlach, Alessandra Larocca, Wee Joo Chng, Pieter Sonneveld, Martin H. van Vliet, Erik H. van Beers
Publikováno v:
International Journal of Laboratory Hematology, 44(1), 127-134. Wiley-Blackwell Publishing Ltd
Objectives: Typically, prognostic capability of gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%-80% of patients are not eligible, possibly limiting the generalizability of findings to routine practice. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01cc7bbb1355dd34009389c28d45d709
https://pure.eur.nl/en/publications/20319b06-72ba-4e40-a8a4-28e4c3b13f2d
https://pure.eur.nl/en/publications/20319b06-72ba-4e40-a8a4-28e4c3b13f2d
Autor:
Annemiek Broijl, Mark-David Levin, Annette W.G. van der Velden, Bronno van der Holt, Pieter Sonneveld, Martin H. van Vliet, Mark van Duin, Sonja Zweegman, H. Berna Beverloo, Jasper Koenders, Anders Waage, Marian Stevens-Kroef, Belinda Dumee, Markus Hansson, Rowan Kuiper, Michael Vermeulen, Heleen Visser-Wisselaar, Erik H. van Beers
Publikováno v:
BLOOD ADVANCES, 4(24), 6298-6309. American Society of Hematology
Blood Adv
Kuiper, R, Zweegman, S, van Duin, M, van Vliet, M H, van Beers, E H, Dumee, B, Vermeulen, M, Koenders, J, van der Holt, B, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Berna Beverloo, H, Stevens-Kroef, M, Levin, M D, Broijl, A, Waage, A & Sonneveld, P 2020, ' Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma : The HOVON-87/NMSG-18 trial ', BLOOD ADVANCES, vol. 4, no. 24, pp. 6298-6309 . https://doi.org/10.1182/bloodadvances.2020002838
Blood Advances, 4, 24, pp. 6298-6309
Blood advances, 4(24), 6298-6309. American Society of Hematology
Blood Advances, 4, 6298-6309
Blood Adv
Kuiper, R, Zweegman, S, van Duin, M, van Vliet, M H, van Beers, E H, Dumee, B, Vermeulen, M, Koenders, J, van der Holt, B, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Berna Beverloo, H, Stevens-Kroef, M, Levin, M D, Broijl, A, Waage, A & Sonneveld, P 2020, ' Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma : The HOVON-87/NMSG-18 trial ', BLOOD ADVANCES, vol. 4, no. 24, pp. 6298-6309 . https://doi.org/10.1182/bloodadvances.2020002838
Blood Advances, 4, 24, pp. 6298-6309
Blood advances, 4(24), 6298-6309. American Society of Hematology
Blood Advances, 4, 6298-6309
The standard prognostic marker for multiple myeloma (MM) patients is the revised International Staging System (R-ISS). However, there is room for improvement in guiding treatment. This applies particularly to older patients, in whom the benefit/risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72d91dfe1cea92994dc30642ab1625ba
https://research.vumc.nl/en/publications/2847a289-5ff2-4097-9696-709d941b5191
https://research.vumc.nl/en/publications/2847a289-5ff2-4097-9696-709d941b5191
Autor:
Martin H. van Vliet, Pieter Sonneveld, Annemiek Broijl, Tom Cupedo, Mark van Duin, Erik H. van Beers, Rowan Kuiper, Sonja Zweegman, B Beverloo
Publikováno v:
Blood. 136:24-25
Background Updating prognostic models for multiple myeloma is important in the context of changing treatment options. Previously we have described the value of the prognostic marker SKY92, which identifies high-risk multiple myeloma patients, as well
Autor:
Marieke Spaan, Torsten Haferlach, Mark van Duin, Martin H. van Vliet, Elena Zamagni, Erik T. Valent, Stefania Oliva, Rowan Kuiper, Pieter Sonneveld, Carolina Terragna, Alessandra Larocca, Yan-Ting Chen, Anders Waage, Erik H. van Beers, Wee Joo Chng, Michele Cavo
Publikováno v:
Blood. 136:23-24
Background: Multiple Myeloma (MM) is a rare and heterogeneous blood cancer of the plasma cells. Various new therapies have been introduced and are used in combination to combat the heterogeneity. Despite ongoing research and the development of innova
Autor:
Martin H. van Vliet, Pieter Sonneveld, Yan-Ting Chen, Rowan Kuiper, Alessandra Larocca, Wee Joo Chng, Erik H. van Beers, Erik T. Valent, Torsten Haferlach, Stefania Oliva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e60-e61
Autor:
Marian Stevens-Kroef, Markus Hansson, Heleen Visser, Pieter Sonneveld, Bronno van der Holt, Anders Waage, Annemiek Broijl, Mark van Duin, Annette W.G. van der Velden, Erik H. van Beers, Martin H. van Vliet, Mark-David Levin, Rowan Kuiper, Sonja Zweegman, Jasper Koenders, Michael Vermeulen, Belinda Dumee, H. Berna Beverloo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Autor:
Martin H. van Vliet, Annemiek Broijl, Joske Ubels, Pieter Sonneveld, Jeroen de Ridder, Erik H. van Beers
Publikováno v:
Nature Communications
Nature Communications, Vol 9, Iss 1, Pp 1-10 (2018)
Nature Communications, 9:2943. Nature Publishing Group
Nature Communications, Vol 9, Iss 1, Pp 1-10 (2018)
Nature Communications, 9:2943. Nature Publishing Group
Many cancer treatments are associated with serious side effects, while they often only benefit a subset of the patients. Therefore, there is an urgent clinical need for tools that can aid in selecting the right treatment at diagnosis. Here we introdu
Autor:
Rowan Kuiper, Shaji Kumar, Paul G. Richardson, Martin H. van Vliet, David S. Siegel, Ravi Vij, Leonie de Best, Joan Levy, Rafael Fonseca, Sundar Jagannath, Donna E. Reece, Suzanne Trudel, Erik H. van Beers, Andrzej Jakubowiak, Sagar Lonial, A. Keith Stewart, Daniel Auclair, Ajai Chari, Kenneth C. Anderson, Todd M. Zimmerman
Publikováno v:
Clinical lymphoma, myelomaleukemia. 17(9)
Background High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify high and low risk disease must be validated in representativ